Amgen updates phase 2 obesity data, shares closely watched by health investors

By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-27, 13:15.

Amgen Inc. (US0311621009) has drawn investor attention after presenting updated phase 2 data for its obesity drug candidate maridebart cafraglutide, with detailed weight-loss and safety outcomes released at a major medical meeting as multiple sources report. The biotech group, whose stock trades on the NASDAQ alongside peers such as Eli Lilly and Novo Nordisk, is positioning the injectable therapy as a potential entrant in the fast-growing market for anti-obesity medicines.

What Reuters and Amgen report

According to a recent Reuters report on Amgen's obesity program, the company shared new phase 2 trial data for maridebart cafraglutide in adults with obesity, covering changes in body weight as well as tolerability over several months of treatment. In the trial, participants receiving the investigational therapy achieved double-digit percentage reductions in body weight on average across select dose groups, with the highest dose showing the most pronounced effect over the study period as summarized in the coverage.

Amgen's own materials on its pipeline, available via an company news release on obesity trial results, highlight that gastrointestinal side effects such as nausea and vomiting were observed but described as generally manageable, echoing patterns seen with other incretin-based therapies. The company also emphasized that no unexpected safety signals were identified in the phase 2 dataset according to its summary, a point that will be closely studied by clinicians and regulators as the program moves forward.

Analyst reactions and sector context

Analyst commentary from firms following the obesity drug space, including a detailed note cited by Bloomberg coverage of the new data, indicates that the weight-loss efficacy reported by Amgen is being compared against leading marketed products such as Eli Lilly's tirzepatide and Novo Nordisk's semaglutide. Some analysts cited in the article characterize the results as promising yet still early, pointing out that larger phase 3 studies and head-to-head comparisons would be required to fully assess competitive positioning and potential commercial impact over the coming years.

Market observers also note that Amgen's broader portfolio, which includes established therapies in oncology and inflammation, may help support the investment needed to advance maridebart cafraglutide through later-stage trials. A consensus summary on the biotech group cited by MarketScreener's analyst consensus page for Amgen shows a mix of Buy and Hold ratings from major houses, with long-term forecasts factoring in potential upside from obesity but still anchored in its existing product franchises and pipeline diversification.

The obesity pipeline in Amgen's strategy

Obesity is increasingly seen as a core strategic field for global biopharma companies, and Amgen's work on maridebart cafraglutide fits into this broader repositioning of portfolios towards metabolic and chronic disease segments. Industry data reproduced in recent sector analyses point to billions of dollars in annual sales potential for effective, safe and scalable obesity treatments, with the combined revenue of competitors such as Eli Lilly and Novo Nordisk already showing strong growth as prescriptions rise in key markets.

From a long-term perspective, Amgen's obesity program adds another pillar to a pipeline that also covers oncology, inflammatory diseases and bone health, areas where the company has historically generated substantial cash flows and invested heavily in research. Investor presentations over the past quarters have highlighted that management aims to balance near-term earnings contributions from established brands with medium-term growth from late-stage pipeline assets, and obesity sits within this medium-term category as trial data accumulate.

What the company sells

Amgen generates revenue through a portfolio of biologic and targeted therapies across oncology, inflammation, bone health and cardiovascular disease, with products such as Prolia for osteoporosis and Repatha for lowering LDL cholesterol acting as major commercial anchors. These therapies are used by specialists and primary-care physicians worldwide, and they rely on advanced manufacturing and distribution capabilities that the company continues to expand as it adds new indications and geographies.

Where the stock trades today

Amgen Inc. shares are listed on the NASDAQ under the ticker AMGN, with the stock quoted in US dollars; as of the latest available trading data for 2026-06-26, the shares last changed hands at 305.00 USD according to exchange information.

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.